SPTX Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leverag…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ... PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year. | ||
 PureTech Health H1 Earnings Call Highlights PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entit | ||
 Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls | ||
 Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third. | ||